Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People whose melanoma has spread (metastatic) and has been confirmed through a tissue or cell sample test
- People whose melanoma is classified as stage IIID (cannot be surgically removed) or stage IV, according to a standard cancer staging system called the AJCC 8th edition
- People who are reasonably active and able to carry out daily activities (rated 0–2 on a standard medical scale called ECOG — confirm with trial site)
- People who are starting their first course of immunotherapy treatment for melanoma, using one of three specific medicines: pembrolizumab, nivolumab, or a combination of ipilimumab and nivolumab
- People who have had a CT or PET-CT scan within 4 weeks before starting treatment
- People who have given their written agreement to take part in the trial
Who may not be able to join:
- People who have previously received systemic (whole-body) treatment for melanoma
- People whose general health and activity level is severely limited (rated 3–4 on the ECOG scale — confirm with trial site)
- People for whom immunotherapy is considered medically unsuitable — for example, those with immune system disorders, people currently on medicines that suppress the immune system, or people with an active autoimmune disease that requires ongoing treatment
- People with another active cancer, except those who have been fully cured of certain skin cancers (basal cell or squamous cell carcinoma), or people who have had another solid tumour with no return of cancer for more than 3 years
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +386 1 587 9000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Objective Response Rate (ORR) According to irRECIST
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.